Fig 1.
Legend: HCV+ = hepatitis C viral positive; CMED = co—medications; CMOR = comorbidities; SVR = sustained virological response; Light grey box = first-generation pangenotypic DAAs; SOF+SMV = sofosbuvir and simeprevir; SOF+DCV = sofosbuvir and daclatasvir; SOF+LDV = sofosbuvir and ledipasvir; SOF+VEL: sofosbuvir and velpatasvir; EBR+GZR = elbasvir and grazoprevir; 2 D Regimen = OBV/PTV/r = ombitasvir, paritaprevir and ritonavir (r); 3D Regimen = 2D+DSV = ombitasvir/paritaprevir/r/dasabuvir; Dark grey box: second generation DAAs; GLE+PIB: glecaprevir/pibrentasvir; SOF+VEL+VOX = sofosbuvir/velpatasvir/voxilaprevir; DAA = direct-acting antivirals; EA = adverse events; med = medications; Dark orange box = main variables; Light orange box = outcomes.
Table 1.
General description of the main comorbidities.
Fig 2.
Comedications according to age group.
Legend: CMED: comedications; P25-P75: interquartile range (percentiles 25th - 75th); Kruskal-Wallis test (Dunn post hoc): p≤0.0001. Significance set at 5% for all analysis. Different letters (ab) indicate Statistical significance.
Table 2.
Interactions with DAAs in the real life cohort.
Table 3.
Distribution of the interactions found according to the scheme DAAs.
Table 4.
Interactions according to physiological system.
Table 5.
Published studies on drug interactions with direct-acting antivirals in hepatitis C patients.